SG11201903795WA - Salts of indazole derivative and crystals thereof - Google Patents
Salts of indazole derivative and crystals thereofInfo
- Publication number
- SG11201903795WA SG11201903795WA SG11201903795WA SG11201903795WA SG11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- crystals
- pct
- salts
- eisai
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016229635 | 2016-11-28 | ||
| PCT/JP2017/042335 WO2018097273A1 (en) | 2016-11-28 | 2017-11-27 | Salts of indazole derivative and crystals thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903795WA true SG11201903795WA (en) | 2019-05-30 |
Family
ID=62195940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903795WA SG11201903795WA (en) | 2016-11-28 | 2017-11-27 | Salts of indazole derivative and crystals thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10640483B2 (ja) |
| EP (1) | EP3544967B1 (ja) |
| JP (1) | JP6346368B1 (ja) |
| KR (1) | KR102425785B1 (ja) |
| CN (1) | CN109790141B (ja) |
| AU (1) | AU2017363699B2 (ja) |
| CA (1) | CA3041986A1 (ja) |
| ES (1) | ES2954879T3 (ja) |
| IL (1) | IL266003B (ja) |
| MX (1) | MX2019004967A (ja) |
| RU (1) | RU2747399C2 (ja) |
| SG (1) | SG11201903795WA (ja) |
| WO (1) | WO2018097273A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102425785B1 (ko) | 2016-11-28 | 2022-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 인다졸 유도체의 염 및 이의 결정 |
| WO2019225552A1 (en) * | 2018-05-22 | 2019-11-28 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| WO2019235564A1 (ja) | 2018-06-06 | 2019-12-12 | 日本電信電話株式会社 | 加入者線端局装置及び帯域割り当て方法 |
| WO2020242795A1 (en) | 2019-05-24 | 2020-12-03 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor |
| WO2022098953A1 (en) * | 2020-11-06 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Method of treating breast cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3907290A1 (de) | 1989-03-07 | 1990-09-13 | Gerhard Prof Dr Eisenbrand | Steroidhormonrezeptoraffine antitumorwirkstoffe |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| US8063249B1 (en) | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
| CA2775266C (en) | 2009-10-13 | 2013-12-31 | Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania | Anti-cancer tamoxifen-melatonin hybrid ligand |
| JP5750050B2 (ja) * | 2009-12-04 | 2015-07-15 | 大正製薬株式会社 | ２−ピリドン化合物 |
| US8222416B2 (en) * | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| WO2011129837A1 (en) | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| UA112425C2 (uk) * | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| WO2013142266A1 (en) | 2012-03-20 | 2013-09-26 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| EP3010501B1 (en) | 2013-06-19 | 2021-11-03 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| EP3010502B1 (en) | 2013-06-19 | 2018-11-21 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CN106572990A (zh) | 2014-03-13 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 含有雌激素受体调节剂的治疗性组合产品 |
| WO2016055982A1 (en) * | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| HUE056199T2 (hu) * | 2015-05-29 | 2022-01-28 | Eisai R&D Man Co Ltd | Tetraszubsztituált alkénvegyületek és alkalmazásuk |
| EP3544974A1 (en) | 2016-11-24 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use for the treatment of breast cancer |
| KR102425785B1 (ko) | 2016-11-28 | 2022-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 인다졸 유도체의 염 및 이의 결정 |
| SG11201908531WA (en) * | 2017-03-16 | 2019-10-30 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of breast cancer |
-
2017
- 2017-11-27 KR KR1020197009419A patent/KR102425785B1/ko active IP Right Grant
- 2017-11-27 IL IL266003A patent/IL266003B/en unknown
- 2017-11-27 AU AU2017363699A patent/AU2017363699B2/en active Active
- 2017-11-27 MX MX2019004967A patent/MX2019004967A/es unknown
- 2017-11-27 SG SG11201903795WA patent/SG11201903795WA/en unknown
- 2017-11-27 WO PCT/JP2017/042335 patent/WO2018097273A1/en active Application Filing
- 2017-11-27 US US16/096,136 patent/US10640483B2/en active Active
- 2017-11-27 EP EP17873875.3A patent/EP3544967B1/en active Active
- 2017-11-27 CA CA3041986A patent/CA3041986A1/en active Pending
- 2017-11-27 RU RU2019112080A patent/RU2747399C2/ru active
- 2017-11-27 ES ES17873875T patent/ES2954879T3/es active Active
- 2017-11-27 CN CN201780057482.6A patent/CN109790141B/zh active Active
- 2017-11-27 JP JP2017226501A patent/JP6346368B1/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019112080A (ru) | 2020-12-28 |
| BR112019008489A2 (pt) | 2019-09-10 |
| IL266003A (en) | 2019-06-30 |
| CN109790141B (zh) | 2021-06-11 |
| CA3041986A1 (en) | 2018-05-31 |
| EP3544967A1 (en) | 2019-10-02 |
| WO2018097273A1 (en) | 2018-05-31 |
| EP3544967A4 (en) | 2020-05-20 |
| AU2017363699A1 (en) | 2019-04-18 |
| US10640483B2 (en) | 2020-05-05 |
| MX2019004967A (es) | 2019-08-22 |
| JP2018108981A (ja) | 2018-07-12 |
| RU2747399C2 (ru) | 2021-05-04 |
| CN109790141A (zh) | 2019-05-21 |
| KR102425785B1 (ko) | 2022-07-28 |
| KR20190084941A (ko) | 2019-07-17 |
| EP3544967B1 (en) | 2023-06-28 |
| IL266003B (en) | 2022-08-01 |
| RU2019112080A3 (ja) | 2020-12-28 |
| ES2954879T3 (es) | 2023-11-27 |
| JP6346368B1 (ja) | 2018-06-20 |
| US20190144419A1 (en) | 2019-05-16 |
| AU2017363699B2 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903795WA (en) | Salts of indazole derivative and crystals thereof | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201408261UA (en) | Syringe | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |